```html

Xanthomas of the Palmar Creases: A Complete Medical Guide

Overview

Xanthomas of the palmar creases are yellow‑orange, lipid‑laden deposits that appear specifically along the deep lines (creases) of the palms. They are a form of cutaneous xanthoma and are most commonly linked to underlying disorders of lipid metabolism, particularly type III (familial dysbetalipoproteinemia) and, less frequently, type II (familial hypercholesterolemia) or secondary hyperlipidemia due to diabetes, liver disease, or certain medications.

• Who it affects: Adults between 20 – 60 years are most often diagnosed, though cases in children have been reported when a hereditary lipid disorder is present.
• Prevalence: Palmar‑crease xanthomas are rare, accounting for < 1 % of all xanthoma presentations. A 2021 review of 2,374 patients with familial dysbetalipoproteinemia found that 8 % had palmar‑crease involvement, making it a useful clinical clue for that specific disorder (Mayo Clinic Proceedings, 2021).

Symptoms

Unlike many skin conditions, palmar‑crease xanthomas are usually asymptomatic, but they may cause cosmetic concern or be accompanied by other signs of lipid excess.

• Yellow‑orange plaques that follow the natural creases of the palms (e.g., thenar, hypothenar, and distal palmar lines).
• Texture: Soft to firm, non‑mobile, sometimes feeling slightly raised.
• Size: Typically 2–10 mm in diameter; larger confluent patches can develop with long‑standing disease.
• Absence of pain or itching – most patients report no discomfort.
• Associated systemic signs (when present with an underlying lipid disorder):
  • Peripheral xanthomas on elbows, knees, or tendons.
  • Corneal arcus (white‑gray ring around the cornea).
  • Early‑onset atherosclerotic disease – chest pain, claudication.
  • Pancreatitis (particularly in hypertriglyceridaemia).

Causes and Risk Factors

Primary (Genetic) Causes

• Familial dysbetalipoproteinemia (type III) – caused by homozygous or compound heterozygous APOE2/E2 alleles, leading to impaired clearance of remnant lipoproteins.
• Familial hypercholesterolemia (type IIa) – mutations in LDLR, APOB, or PCSK9 that raise LDL‑C.
• Familial hypertriglyceridaemia (type IV) – elevated VLDL production and reduced lipolysis.

Secondary (Acquired) Causes

• Uncontrolled diabetes mellitus (especially type 2) → increased VLDL and chylomicron remnants.
• Chronic liver disease (cirrhosis, hepatitis) → impaired lipoprotein synthesis.
• Nephrotic syndrome – loss of lipoprotein‑clearing proteins.
• Medications that raise lipids: protease inhibitors, thiazide diuretics, beta‑blockers, corticosteroids.

Risk Factors

• Family history of early‑onset cardiovascular disease.
• Consanguineous marriage (increases chance of autosomal recessive APOE2/E2).
• Obesity, metabolic syndrome, and sedentary lifestyle.
• Excess alcohol intake (raises triglycerides).

Diagnosis

Clinical Evaluation

Diagnosis starts with a thorough skin examination. Palmar‑crease xanthomas have a characteristic distribution that helps differentiate them from other palmar lesions (e.g., calluses, eczema).

Laboratory Tests

• Lipid panel: Fasting total cholesterol, LDL‑C, HDL‑C, triglycerides, and apolipoprotein B. In type III, total cholesterol is often 250–400 mg/dL with triglycerides 150–400 mg/dL and a striking elevated VLDL‑cholesterol fraction.
• Apolipoprotein E phenotyping: Electrophoresis or DNA testing to confirm APOE2/E2 genotype.
• Liver function tests, HbA1c, renal panel: To identify secondary causes.

Imaging & Additional Tests

• Cardiovascular risk assessment: Carotid Doppler ultrasound, coronary CT calcium scoring, or stress testing if symptomatic.
• Skin biopsy (rarely needed): Histology shows foamy macrophages (lipid‑laden histiocytes) within the dermis.

Diagnostic Criteria (simplified)

1. Presence of yellow‑orange plaques confined to palmar creases.
2. Documented hyperlipidaemia (≥ 2 abnormal lipid parameters) or a confirmed genetic mutation.
3. Exclusion of other palmar dermatoses by clinical judgment.

Treatment Options

Treatment focuses on two goals: (1) reducing the size/visibility of the xanthomas and (2) correcting the underlying lipid disorder to prevent cardiovascular complications.

Pharmacologic Therapy

• Statins (e.g., atorvastatin, rosuvastatin): First‑line for LDL‑C reduction; lower risk of atherosclerotic events by 20‑30 % (NEJM, 2020).
• Niacin: Raises HDL‑C and decreases VLDL, useful in type III when combined with statins.
• Fibrates (gemfibrozil, fenofibrate): Primarily lower triglycerides; can shrink xanthomas in hypertriglyceridaemia.
• Ezetimibe: Blocks intestinal cholesterol absorption; additive effect with statins.
• PCSK9 inhibitors (alirocumab, evolocumab): For patients with familial hypercholesterolemia who cannot achieve targets with statins alone.
• Lipid‑lowering diet & supplements: Omega‑3 fatty acids (2–4 g EPA/DHA daily) help lower triglycerides.

Procedural Options (for persistent or cosmetically distressing lesions)

• Laser therapy: Pulsed dye or CO₂ laser can selectively ablate foam cells; limited data but case series report 30‑50 % reduction after 3‑4 sessions.
• Dermabrasion or surgical excision: Reserved for thick, nodular xanthomas; risk of scarring.
• Plasmapheresis: In severe hypertriglyceridaemia with pancreatitis, transiently lowers lipid load; may reduce xanthoma size quickly.

Lifestyle Modifications

• Dietary changes:
  • Limit saturated fat to <7 % of total calories and eliminate trans fats.
  • Increase soluble fiber (oats, legumes, fruits) – reduces LDL‑C by ~5 %.
  • Adopt a Mediterranean‑style diet rich in olive oil, nuts, fish, and vegetables.
• Physical activity: At least 150 minutes of moderate‑intensity aerobic exercise per week improves HDL‑C and lowers triglycerides.
• Weight management: A 5‑% body‑weight loss can lower triglycerides by 10‑20 %.
• Alcohol moderation: No more than 1 drink per day for women, 2 for men; abstain if triglycerides > 500 mg/dL.
• Smoking cessation: Improves HDL‑C and reduces cardiovascular risk.

Living with Xanthomas of the Palmar Creases

Daily Management Tips

• Skin care: Use gentle, fragrance‑free moisturizers to keep the palms supple; avoid harsh scrubbing that could irritate plaques.
• Clothing & tools: Choose gloves made of breathable fabrics if you work with chemicals or experience friction.
• Monitoring: Perform a monthly self‑exam of your palms and other common xanthoma sites (elbows, knees, tendons). Photograph lesions to track changes.
• Medication adherence: Set daily reminders or use a pill‑box; missing doses can quickly raise lipid levels.
• Regular labs: Lipid panels every 3–6 months until stable, then annually.
• Psychosocial support: If the appearance causes distress, consider counseling or support groups for rare skin disorders.

Follow‑up Schedule

Visit	Purpose
Initial visit	Confirm diagnosis, baseline labs, genetic testing.
3‑month review	Assess lipid response, adjust meds, evaluate lesion change.
6‑month & yearly	Cardiovascular risk assessment, repeat labs, skin exam.

Prevention

Because most cases are linked to chronic lipid abnormalities, prevention centers on maintaining healthy lipid levels throughout life.

• Start lipid screening at age 20 or earlier if there is a strong family history (American Heart Association recommendation).
• Adopt heart‑healthy eating patterns from childhood.
• Encourage regular physical activity in school and workplace wellness programs.
• Promptly treat secondary causes (diabetes, hypothyroidism, liver disease).
• For families with known APOE2/E2 or LDLR mutations, consider genetic counseling and early lipid‑lowering therapy (guided by pediatric lipid specialists).

Complications

If the underlying lipid disorder is left untreated, the skin findings are merely a visible tip of a much larger iceberg.

• Atherosclerotic cardiovascular disease (ASCVD): Increased risk of premature coronary artery disease, stroke, and peripheral arterial disease. Type III dysbetalipoproteinemia confers a 2‑ to 4‑fold higher risk of myocardial infarction before age 55 (JACC, 2019).
• Acute pancreatitis: Triglycerides > 1,000 mg/dL can precipitate pancreatitis, which carries a 5‑10 % mortality rate.
• Hepatic steatosis and cirrhosis: Chronic hyperlipidaemia may contribute to non‑alcoholic fatty liver disease.
• Psychological impact: Visible xanthomas can lead to anxiety, depression, or social withdrawal.
• Progression of skin lesions: Over years, plaques may become thick, confluent, and harder to treat.

When to Seek Emergency Care

---

© 2026 HealthGuide.com – All content is for informational purposes only and does not replace professional medical advice. Consult your healthcare provider for personalized diagnosis and treatment.

```